 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > SafeScience, Inc.
 |
SafeScience, Inc. |
 |
 |
 |
PROFILE |
 |
SafeScience is pumped up on carbs. The development-stage biotechnology company is working on various drug candidates through subsidiary International Gene Group. Its pipeline includes lead drug candidate GBC-590, a complex-carbohydrate glycoprotein being tested as a possible treatment for various cancers. Another drug candidate, CAN-296, is a complex carbohydrate topical anti-fungal treatment. The firm has shut down and plans to sell subsidiary SafeScience Products, which focused on marketing and developing organically safe products such as cleaning supplies for consumer and industrial customers, as well as agricultural and horticultural fungicides and fertilizers.
COMPETITION |
 |
Neose Technologies, Inc. (NTEC)
Novartis AG (NVS)
Versicor Inc. (VERS)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 0.10
1-Yr. Sales Growth: (92.9)%
Employees: 30
Revenue per employee: $3,333.33
KEY PEOPLE |
 |
Bradley J. Carver
CEO
John W. Burns
CFO
CONTACT INFO |
 |
Park Square Bldg., 31 St. James Ave., 8th Fl.
Boston, MA 02116
US
Phone: 617-422-0674
Fax: 617-422-0675
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |